1型糖尿病成人中甘精胰岛素300单位/mL与100单位/mL的比较:使用晨间或晚间注射的持续葡萄糖监测图谱与变异性
这项16周探索性开放标签平行分组两周期交叉研究纳入59例1型糖尿病成人,随机分配至每日一次甘精胰岛素300单位/mL或100单位/mL晨间或晚间注射。结果显示两组目标血糖范围时间百分比相当,甘精胰岛素300单位/mL在24小时注射间期最后4小时CGM葡萄糖升高显著更少,24小时葡萄糖曲线更平滑,夜间低血糖发生率更低。
要点
- 甘精胰岛素300单位/mL与100单位/mL在目标血糖范围时间百分比上相当。
- 甘精胰岛素300单位/mL在24小时注射间期最后4小时CGM葡萄糖升高显著更少。
- 甘精胰岛素300单位/mL夜间确证或严重低血糖发生率低于100单位/mL。
核心结论
- 与甘精胰岛素100单位/mL相比,甘精胰岛素300单位/mL在24小时注射间期最后4小时CGM葡萄糖升高更少,24小时平均葡萄糖曲线更平滑(无论注射时间),且夜间低血糖更少。
研究设计与样本
- 16周探索性开放标签平行分组两周期交叉研究(clinicaltrials.gov标识NCT01658579),59例1型糖尿病成人按1:1:1:1随机分配至每日一次甘精胰岛素300单位/mL或100单位/mL晨间或晚间注射(注射方案交叉)。
- 主要疗效终点为每个8周周期最后2周经持续葡萄糖监测(CGM)测量的目标葡萄糖范围(80-140 mg/dL)内时间平均百分比。
主要发现
- 目标葡萄糖范围内时间百分比在甘精胰岛素300单位/mL组与100单位/mL组之间相当。
- 24小时注射间期最后4小时CGM葡萄糖升高在甘精胰岛素300单位/mL组显著少于100单位/mL组(最小二乘均值差-14.7 mg/dL [95%CI -26.9至-2.5];P=0.0192)。
- 甘精胰岛素300单位/mL组24小时平均葡萄糖曲线更平滑(血糖波动更低),无论晨间或晚间注射。
- 四项受试者内间质葡萄糖变异性指标在甘精胰岛素300单位/mL与100单位/mL之间无差异。
- 夜间确证(自测血浆葡萄糖<54 mg/dL)或严重低血糖发生率在甘精胰岛素300单位/mL组低于100单位/mL组(每参与者年4.0 vs 9.0次事件;率比0.45 [95%CI 0.24-0.82])。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objective of this study was to compare glucose control in participants with type 1 diabetes receiving insulin glargine 300 units/mL (Gla-300) or glargine 100 units/mL (Gla-100) in the morning or evening, in combination with mealtime insulin. RESEARCH DESIGN AND METHODS: In this 16-week, exploratory, open-label, parallel-group, two-period crossover study (clinicaltrials.gov identifier NCT01658579), 59 adults with type 1 diabetes were randomized (1:1:1:1) to once-daily Gla-300 or Gla-100 given in the morning or evening (with crossover in the injection schedule). The primary efficacy end point was the mean percentage of time in the target glucose range (80-140 mg/dL), as measured using continuous glucose monitoring (CGM), during the last 2 weeks of each 8-week period. Additional end points included other CGM glycemic control parameters, hypoglycemia (per self-monitored plasma glucose [SMPG]), and adverse events. RESULTS: The percentage of time within the target glucose range was comparable between the Gla-300 and Gla-100 groups. There was significantly less increase in CGM-based glucose during the last 4 h of the 24-h injection interval for Gla-300 compared with Gla-100 (least squares mean difference -14.7 mg/dL [95% CI -26.9 to -2.5]; P = 0.0192). Mean 24-h glucose curves for the Gla-300 group were smoother (lower glycemic excursions), irrespective of morning or evening injection. Four metrics of intrasubject interstitial glucose variability showed no difference between Gla-300 and Gla-100. Nocturnal confirmed (<54 mg/dL by SMPG) or severe hypoglycemia rate was lower for Gla-300 participants than for Gla-100 participants (4.0 vs. 9.0 events per participant-year; rate ratio 0.45 [95% CI 0.24-0.82]). CONCLUSIONS: Less increase in CGM-based glucose levels in the last 4 h of the 24-h injection interval, smoother average 24-h glucose profiles irrespective of injection time, and reduced nocturnal hypoglycemia were observed with Gla-300 versus Gla-100.
引用
- Bergenstal RM, Bailey TS, Rodbard D, et al. Comparison of Insulin Glargine 300 Units/mL and 100 Units/mL in Adults With Type 1 Diabetes: Continuous Glucose Monitoring Profiles and Variability Using Morning or Evening Injections. Diabetes Care. 2017. PMID: 28115474. doi:10.2337/dc16-0684
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。